# Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas

> **NCT02055924** · PHASE1 · TERMINATED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 85 (actual)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib and immunochemotherapies

## Key facts

- **NCT ID:** NCT02055924
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-26
- **Primary completion:** 2017-12-01
- **Final completion:** 2018-10-09
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** ANSM decision due to veino occlusive disease (security alert)
- **Last updated:** 2018-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02055924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02055924, "Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02055924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*